The stock price of Bausch Health Companies Inc (NYSE: BHC) has dropped by -2.76 compared to previous close of 8.69. Despite this, the company has seen a fall of -2.09% in its stock price over the last five trading days. Accesswire reported 2024-04-11 that LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.
Is It Worth Investing in Bausch Health Companies Inc (NYSE: BHC) Right Now?
BHC has 36-month beta value of 0.91. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BHC is 356.59M, and currently, short sellers hold a 6.31% ratio of that float. The average trading volume of BHC on April 23, 2024 was 2.76M shares.
BHC’s Market Performance
BHC’s stock has seen a -2.09% decrease for the week, with a -11.05% drop in the past month and a 2.80% gain in the past quarter. The volatility ratio for the week is 3.52%, and the volatility levels for the past 30 days are at 5.64% for Bausch Health Companies Inc The simple moving average for the past 20 days is -11.06% for BHC’s stock, with a 1.82% simple moving average for the past 200 days.
Analysts’ Opinion of BHC
Many brokerage firms have already submitted their reports for BHC stocks, with Jefferies repeating the rating for BHC by listing it as a “Buy.” The predicted price for BHC in the upcoming period, according to Jefferies is $16 based on the research report published on September 20, 2023 of the previous year 2023.
BHC Trading at -8.50% from the 50-Day Moving Average
After a stumble in the market that brought BHC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.27% of loss for the given period.
Volatility was left at 5.64%, however, over the last 30 days, the volatility rate increased by 3.52%, as shares sank -11.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.94% upper at present.
During the last 5 trading sessions, BHC fell by -2.09%, which changed the moving average for the period of 200-days by +9.88% in comparison to the 20-day moving average, which settled at $9.45. In addition, Bausch Health Companies Inc saw 5.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BHC starting from Carson Seana, who sale 6,313 shares at the price of $9.80 back on Mar 04 ’24. After this action, Carson Seana now owns 499,905 shares of Bausch Health Companies Inc, valued at $61,867 using the latest closing price.
Carson Seana, the EVP, General Counsel of Bausch Health Companies Inc, sale 220 shares at $7.38 during a trade that took place back on Dec 05 ’23, which means that Carson Seana is holding 382,925 shares at $1,624 based on the most recent closing price.
Stock Fundamentals for BHC
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 1.0 for the gross margin
The net margin for Bausch Health Companies Inc stands at -0.02. The total capital return value is set at 0.04.
Based on Bausch Health Companies Inc (BHC), the company’s capital structure generated 1.05 points at debt to capital in total, while cash flow to debt ratio is standing at 0.05. The debt to equity ratio resting at -21.91. The interest coverage ratio of the stock is -0.73.
Currently, EBITDA for the company is 2.89 billion with net debt to EBITDA at -17.68. When we switch over and look at the enterprise to sales, we see a ratio of 2.8. The receivables turnover for the company is 4.38for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.30.
Conclusion
To put it simply, Bausch Health Companies Inc (BHC) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
